Lipid-Modified Bilirubin Nanocrystals for the Repair of Ischemia-Reperfusion-Induced Acute Kidney Injury
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Renxiang Yuan und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Reperfusion Injury, Nanoparticles, Bilirubin. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, Medical and Health Research Project of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ischemia-reperfusion (IR)-induced acute kidney injury (AKI) is a life-threatening form of AKI frequently observed in clinical settings, such as hemorrhagic shock, kidney transplantation, and cardiovascular surgery. Targeting renal antioxidant therapy may represent an effective strategy against IR-induced AKI. Bilirubin (BR), a specific superoxide anion scavenger, faces limitations in clinical application due to its poor water solubility and hepatic metabolism pathway. In this study, we prepared bilirubin nanocrystals (BRNCs), which demonstrated potent antioxidant effects in vitro experiments. To enhance renal targeting, BRNCs were encapsulated in poly(ethylene glycol) (PEG)-modified lipid nanoparticle (BRNC-LNP). In vivo distribution studies revealed that BRNC-LNP effectively circumvented hepatic metabolism and exhibited enhanced renal accumulation compared to BRNC. In vivo efficacy evaluation revealed superior therapeutic outcomes with BRNC-LNP versus BRNC in AKI mice. These findings suggest that BRNC-LNP may serve as a promising therapeutic strategy for IR-induced AKI by reducing the level of hepatic metabolism and promoting renal targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China.
- Jinhua Institute of Zhejiang University, Jinhua 321299, P. R. China.
- Department of Pharmacy, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou 311200, P. R. China.
- Department of Clinical Pharmacology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, P. R. China.
- Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou 310003, P. R. China.
ORCID-Profile: Fuqiang Hu, Hong Yuan
Förderung
- Medical Science and Technology Project of Zhejiang Province
- Medical and Health Research Project of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Yuan, R., Yang, S., Wang, D., Yu, C., Li, P., Jiang, Q., Luo, Y., Meng, T., Hu, F., Yu, T., Liu, Y., & Yuan, H. (2025). Lipid-Modified Bilirubin Nanocrystals for the Repair of Ischemia-Reperfusion-Induced Acute Kidney Injury. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00559
Vancouver
Yuan R, Yang S, Wang D, Yu C, Li P, Jiang Q, et al. Lipid-Modified Bilirubin Nanocrystals for the Repair of Ischemia-Reperfusion-Induced Acute Kidney Injury. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00559
BibTeX
@article{Yuan2025,
author = {Yuan, Renxiang and Yang, Shuqian and Wang, Ding and Yu, Caini and Li, Peirong and Jiang, Qi and Luo, Yangqian and Meng, Tingting and Hu, Fuqiang and Yu, Tong and Liu, Yupeng and Yuan, Hong},
title = {Lipid-Modified Bilirubin Nanocrystals for the Repair of Ischemia-Reperfusion-Induced Acute Kidney Injury},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00559}
}
EUVIMED